Aprogen pharmaceuticals,Inc. (003060.KS)
KRW 704.0
(-4.22%)
KRW 704.0
(-4.22%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 87.36 Billion KRW | 34.01% |
| 2022 | 65.19 Billion KRW | 15.42% |
| 2021 | 56.48 Billion KRW | 5.93% |
| 2020 | 53.31 Billion KRW | 4.75% |
| 2019 | 50.9 Billion KRW | 12.13% |
| 2018 | 45.39 Billion KRW | -1.53% |
| 2017 | 46.1 Billion KRW | 4.48% |
| 2016 | 44.12 Billion KRW | 9.42% |
| 2015 | 40.32 Billion KRW | 21.85% |
| 2014 | 33.09 Billion KRW | 12.01% |
| 2013 | 29.54 Billion KRW | -12.52% |
| 2012 | 33.76 Billion KRW | -32.63% |
| 2011 | 50.12 Billion KRW | 200.33% |
| 2010 | 16.68 Billion KRW | -73.18% |
| 2009 | 62.22 Billion KRW | 194.4% |
| 2008 | 21.13 Billion KRW | 23.49% |
| 2007 | 17.11 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 15.19 Billion KRW | -2.66% |
| 2024 Q1 | 15.6 Billion KRW | -31.26% |
| 2023 Q2 | 27.07 Billion KRW | 55.14% |
| 2023 Q3 | 20.13 Billion KRW | -25.64% |
| 2023 Q4 | 22.7 Billion KRW | 12.76% |
| 2023 FY | 87.36 Billion KRW | 34.01% |
| 2023 Q1 | 17.45 Billion KRW | 2.15% |
| 2022 FY | 65.19 Billion KRW | 15.42% |
| 2022 Q3 | 16.01 Billion KRW | 5.18% |
| 2022 Q4 | 17.08 Billion KRW | 6.67% |
| 2022 Q2 | 15.22 Billion KRW | -9.7% |
| 2022 Q1 | 16.86 Billion KRW | 17.31% |
| 2021 Q1 | 12.28 Billion KRW | -2.33% |
| 2021 Q2 | 15.15 Billion KRW | 23.43% |
| 2021 Q3 | 14.66 Billion KRW | -3.26% |
| 2021 FY | 56.48 Billion KRW | 5.93% |
| 2021 Q4 | 14.37 Billion KRW | -1.98% |
| 2020 Q2 | 13.49 Billion KRW | -2.5% |
| 2020 FY | 53.31 Billion KRW | 4.75% |
| 2020 Q4 | 12.57 Billion KRW | -6.24% |
| 2020 Q3 | 13.41 Billion KRW | -0.6% |
| 2020 Q1 | 13.83 Billion KRW | -6.13% |
| 2019 Q3 | 12.13 Billion KRW | -4.74% |
| 2019 FY | 50.9 Billion KRW | 12.13% |
| 2019 Q2 | 12.73 Billion KRW | 12.78% |
| 2019 Q1 | 11.29 Billion KRW | -13.1% |
| 2019 Q4 | 14.74 Billion KRW | 21.52% |
| 2018 Q3 | 10.46 Billion KRW | -4.23% |
| 2018 FY | 45.39 Billion KRW | -1.53% |
| 2018 Q1 | 11 Billion KRW | -9.49% |
| 2018 Q2 | 10.92 Billion KRW | -0.72% |
| 2018 Q4 | 12.99 Billion KRW | 24.16% |
| 2017 Q2 | 11.1 Billion KRW | -3.91% |
| 2017 Q3 | 11.28 Billion KRW | 1.66% |
| 2017 FY | 46.1 Billion KRW | 4.48% |
| 2017 Q1 | 11.55 Billion KRW | -3.6% |
| 2017 Q4 | 12.16 Billion KRW | 7.75% |
| 2016 FY | 44.12 Billion KRW | 9.42% |
| 2016 Q1 | 10.6 Billion KRW | -12.93% |
| 2016 Q4 | 11.98 Billion KRW | 15.04% |
| 2016 Q3 | 10.41 Billion KRW | -6.23% |
| 2016 Q2 | 11.11 Billion KRW | 4.73% |
| 2015 Q2 | 9.71 Billion KRW | 1.7% |
| 2015 Q3 | 8.87 Billion KRW | -8.56% |
| 2015 FY | 40.32 Billion KRW | 21.85% |
| 2015 Q4 | 12.18 Billion KRW | 37.21% |
| 2015 Q1 | 9.54 Billion KRW | 21.09% |
| 2014 Q2 | 8.32 Billion KRW | 5.02% |
| 2014 Q3 | 8.95 Billion KRW | 7.53% |
| 2014 FY | 33.09 Billion KRW | 12.01% |
| 2014 Q1 | 7.92 Billion KRW | 79.53% |
| 2014 Q4 | 7.88 Billion KRW | -11.91% |
| 2013 Q4 | 4.41 Billion KRW | -49.5% |
| 2013 Q3 | 8.74 Billion KRW | 3.44% |
| 2013 FY | 29.54 Billion KRW | -12.52% |
| 2013 Q1 | 7.92 Billion KRW | -9.25% |
| 2013 Q2 | 8.45 Billion KRW | 6.63% |
| 2012 Q4 | 8.73 Billion KRW | -0.53% |
| 2012 Q1 | 6.62 Billion KRW | 0.0% |
| 2012 Q2 | 7.74 Billion KRW | 16.98% |
| 2012 Q3 | 8.78 Billion KRW | 13.35% |
| 2012 FY | 33.76 Billion KRW | -32.63% |
| 2011 Q1 | 12.69 Billion KRW | 0.0% |
| 2011 Q2 | 11.42 Billion KRW | -10.05% |
| 2011 Q3 | 8.97 Billion KRW | -21.45% |
| 2011 FY | 50.12 Billion KRW | 200.33% |
| 2011 Q4 | - KRW | -100.0% |
| 2010 Q3 | - KRW | -100.0% |
| 2010 Q1 | 12.38 Billion KRW | 0.67% |
| 2010 FY | 16.68 Billion KRW | -73.18% |
| 2010 Q2 | 13.87 Billion KRW | 12.05% |
| 2009 FY | 62.22 Billion KRW | 194.4% |
| 2009 Q3 | - KRW | -100.0% |
| 2009 Q1 | 10.12 Billion KRW | 17.21% |
| 2009 Q2 | 11.23 Billion KRW | 11.05% |
| 2009 Q4 | 12.3 Billion KRW | 0.0% |
| 2008 Q4 | 8.63 Billion KRW | 0.0% |
| 2008 Q3 | - KRW | -100.0% |
| 2008 FY | 21.13 Billion KRW | 23.49% |
| 2008 Q2 | 3.92 Billion KRW | -19.26% |
| 2008 Q1 | 4.86 Billion KRW | -7.84% |
| 2007 Q3 | 4.53 Billion KRW | -0.15% |
| 2007 Q2 | 4.54 Billion KRW | 22.64% |
| 2007 Q1 | 3.7 Billion KRW | 0.0% |
| 2007 FY | 17.11 Billion KRW | 0.0% |
| 2007 Q4 | 5.27 Billion KRW | 16.35% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 137.2 Billion KRW | 36.328% |
| Dong-A Socio Holdings Co., Ltd. | 1132 Billion KRW | 92.282% |
| Ildong Holdings Co., Ltd. | 638.44 Billion KRW | 86.316% |
| HANDOK Inc. | 522.74 Billion KRW | 83.287% |
| Kukje Pharma Co., Ltd. | 135.37 Billion KRW | 35.464% |
| Yuhan Corporation | 1858.98 Billion KRW | 95.3% |
| Dong-A ST Co., Ltd. | 663.98 Billion KRW | 86.842% |
| SAMSUNG PHARM. Co., LTD. | 51.95 Billion KRW | -68.152% |
| Hanmi Pharm. Co., Ltd. | 1490.88 Billion KRW | 94.14% |
| Hanall Biopharma Co.,Ltd | 134.9 Billion KRW | 35.243% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | 76.422% |
| Dong Sung Bio Pharm.Co.,Ltd. | 88.59 Billion KRW | 1.388% |
| MYUNGMOON Pharm co.,Ltd | 169.56 Billion KRW | 48.479% |
| Hana Pharm Co., Ltd. | 224.45 Billion KRW | 61.078% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | 36.328% |
| Ilsung Pharmaceuticals Co., Ltd. | 78.05 Billion KRW | -11.928% |
| REYON Pharmaceutical Co., Ltd. | 151.07 Billion KRW | 42.171% |
| JW Holdings Corporation | 928.07 Billion KRW | 90.587% |
| Ildong Pharmaceutical Co., Ltd. | 600.75 Billion KRW | 85.458% |
| Chong Kun Dang Pharmaceutical Corp. | 1669.4 Billion KRW | 94.767% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 88.329% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | 56.368% |
| Hyundai Pharmaceutical Co., Ltd. | 180.76 Billion KRW | 51.669% |
| Samil Pharmaceutical Co.,Ltd | 196.34 Billion KRW | 55.505% |
| Jeil Pharmaceutical Co.,Ltd | 726.39 Billion KRW | 87.973% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | 36.328% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1514.45 Billion KRW | 94.231% |
| Daewoong pharmaceutical Co.,Ltd | 1375.32 Billion KRW | 93.648% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 88.329% |
| Yuhan Corporation | 1858.98 Billion KRW | 95.3% |
| Jeil Pharma Holdings Inc | 794.71 Billion KRW | 89.007% |
| Yungjin Pharm. Co., Ltd. | 234.9 Billion KRW | 62.809% |
| Suheung Co., Ltd. | 594.56 Billion KRW | 85.306% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 88.329% |
| Samjin Pharmaceuticals Co., Ltd. | 292.12 Billion KRW | 70.094% |
| Korea United Pharm Inc. | 278.94 Billion KRW | 68.681% |
| CKD Bio Corp. | 160.35 Billion KRW | 45.518% |
| Daewon Pharmaceutical Co., Ltd. | 526.95 Billion KRW | 83.421% |
| Dongwha Pharm.Co.,Ltd | 361.1 Billion KRW | 75.807% |
| Whan In Pharm Co.,Ltd. | 230.39 Billion KRW | 62.081% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | 56.368% |
| Chong Kun Dang Holdings Corp. | 879.78 Billion KRW | 90.07% |
| Boryung Corporation | 859.62 Billion KRW | 89.837% |
| Bukwang Pharmaceutical Co., Ltd. | 125.92 Billion KRW | 30.624% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | 76.422% |
| JW Lifescience Corporation | 206.86 Billion KRW | 57.767% |